Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics (NASDAQ:KPTI) was given a new $12.00 price target on by analysts at The Goldman Sachs Group, Inc..
Karyopharm Therapeutics (NASDAQ:KPTI) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Karyopharm to Participate in Baird's Biotech Discovery Series